麗珠集團(000513.SZ):已完成出售江蘇尼科醫療器械19.99%股權
格隆匯 7 月 1日丨麗珠集團(000513.SZ)公佈,公司於2020年5月27日發佈了《麗珠醫藥集團股份有限公司關於出售江蘇尼科醫療器械有限公司19.99%股權的公告》。
此次出售江蘇尼科醫療器械有限公司股權所需相關工商變更登記及備案手續已辦理完成,公司已於2020年6月30日收到上述股權轉讓款共計美元1722.17萬元(摺合成人民幣約1.22億元)。
經公司初步測算,扣除投資成本、税費等相關費用後此次出售股權預計增加公司歸屬於母公司股東的淨利潤約人民幣8523.99萬元,最終可實現的淨利潤將以公司2020年度審計報告為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.